Followers | 4 |
Posts | 4327 |
Boards Moderated | 0 |
Alias Born | 12/11/2012 |
Saturday, October 19, 2013 12:26:45 PM
VistaGen signed a strategic financing agreement with the European subsidiary of Bergamo Acquisition Corp., a global diversified investment holding company.
VistaGen plans to use proceeds of the financing to accelerate and expand its stem cell technology-based drug rescue programs. Using its innovative CardioSafe(TM) 3D and LiverSafe(TM) 3D bioassay systems and modern medicinal chemistry, VSTA is focused on generating new, safer, proprietary variants (Drug Rescue Variants) of once-promising small molecule drug candidates discontinued in development by large pharmaceutical companies due to heart or liver safety issues. VSTA also plans to advance new pilot nonclinical regenerative cell therapy programs and certain other emerging commercial opportunities related to its Human Clinical Trials in a Test Tube(TM) platform
EXPERIENCE IS THE BEST TEACHER, BUT IT IS THE MOST EXPENSIVE
MY OPINIONS ARE MY OWN AND DUE DILIGENCE I POST SHOULD BE CONFIRMED AS UNBIASED,EVERYTHING POSTED IS OFCOURSE IN MY HUMBLE OPINION
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM